Innate Pharma Sa Share Price

NASDAQ: IPHA

Small Cap

$2.00

-0.08

(-3.85%)

as on September 18, 2025 at 1:28 am IST

$₹

Innate Pharma Sa Stock Performance

as on September 18, 2025 at 1:28 am IST

Day's Low
Day's High
$1.96
Day's Price Range
$2.16
$2
2.00%
Downside
8.00%
Upside
52 Week's Low
52 Week's High
$1.29
52-Week Price Range
$3.51
$2
35.50%
Downside
75.53%
Upside

Innate Pharma Sa share price movements today

Previous Close: $2.08
Open: $2.13
Volume: 288.8K
Day's Low - High: $1.96 - $2.16
52 Week Low - High: $1.29 - $3.51

Innate Pharma Sa Historical Returns

1 Month Return: -5.02 %
3 Month Return: + 8.3 %
1 Year Return: -5.88 %
3 Year Return: -32.25 %
5 Year Return: -50.36 %

Innate Pharma Sa Stock Fundamentals & Key Indicators

Check Innate Pharma Sa market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$196.5M

EPS (TTM)

-0.779

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.75%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

EBITDA

-50.3M

Revenue (TTM)

20.1M

Profit Margin

-245.87%

Return On Equity TTM

1651100.00%

Innate Pharma Sa vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Innate Pharma Sa with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Innate Pharma Sa	BUY	$196.5M	-50.36%	NA	-245.87%
Alnylam Pharmaceuticals, Inc.	BUY	$60.5B	252.04%	-505.15	-12.96%
Beone Medicines Ltd	NA	$39.0B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$100.3B	44.17%	27.85	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.6B	1.78%	14.1	31.37%

Stock Returns calculator for Innate Pharma Sa Stock including INR - Dollar returns

The Innate Pharma Sa stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Innate Pharma Sa investment value today

Current value as on today

₹95,096

Returns

₹4,904

(-4.9%)

Returns from Innate Pharma Sa Stock

₹9,502 (-9.5%)

Dollar Returns*

₹4,598 (+4.6%)

Analyst Recommendation on Innate Pharma Sa Stock

Based on 10 analysts

BUY

70.00%

Buy

30.00%

Hold

0.00%

Sell

Based on 10 analysts, 70% of analysts recommend a 'BUY' rating for Innate Pharma Sa. Average target price of $7.89

Innate Pharma Sa Share Price Target

Get share price movements and forecasts by analysts on Innate Pharma Sa.

What analysts predicted

74.65%UPSIDE

Target Price

$7.89

Current Price

Analyzed by

10 Analysts

Target

$7.89

Innate Pharma Sa target price $7.89, a slight upside of 74.65% compared to current price of $2. According to 10 analysts rating.

Innate Pharma Sa Stock's Interest Amongst Investors

Search interest for Innate Pharma Sa Stock has decreased by -39% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 19, 2025 to September 18, 2025

Change:-39% versus previous 30 day period

Innate Pharma Sa Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Mar 2025
Total Revenue	43	5	8	21	38	10	21	21	12	0
Gross Profit	30	-7	-5	4	21	-1	-3	-3	-16	29
Operating Income	4	-12	-28	0	-5	-6	-12	-12	-26	-25
EBITDA	6	-11	-65	1	0	-5	-10	-10	-25	-21
Interest Expense	-	-	0	0	0	-	3	3	0	0
Depreciation	-	-	-	-	-	-	-	-	-	-
Income Before Tax	2	-32	-68	0	-3	-4	-9	-9	-24	-24
Income Tax Expense	-4	-	-3	-3	-4	-	-9	-9	-	-
Net Income	6	-31	-68	0	1	-4	-9	-9	-24	-24
Net Profit Margin	15.27%	-532.46%	-775.14%	4.27%	4.86%	-43.31%	-43.31%	-43.31%	-200.60%	-8951.81%

Innate Pharma Sa Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	19	59	38	90	76	84	13	61	56	13
Gross Profit	-13	7	-40	11	26	24	-39	-2	-4	13
Operating Income	-10	7	-39	5	-27	1	-47	-57	-12	-51
EBITDA	-8	10	-35	-3	-20	13	-43	-12	-1	-46
Interest Expense	0	0	0	0	0	0	0	0	0	0
Depreciation	-	-	4	7	16	56	4	45	5	1
Income Before Tax	-6	12	-48	2	-20	0	-45	-57	-7	-49
Income Tax Expense	0	0	0	0	0	6	13	41	-9	-
Net Income	-7	13	-57	3	-23	-77	-66	-61	-8	-51
Net Profit Margin	-37.45%	22.51%	-148.28%	3.82%	-30.40%	-91.70%	-488.24%	-100.74%	-14.59%	-391.97%

Innate Pharma Sa Quarterly Cash Flow

All numbers in Millions USD

	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Mar 2025
Net Income	-32	-64	-64	1	-4	-9	-9	-24	-24
Operating Cash Flow	-10	-20	-20	-11	-10	-21	-21	3	-9
Investing Cash Flow	1	2	0	0	-	-	20	0	8
Financing Cash Flow	0	-1	-1	-1	0	0	0	-4	-1
Change in Cash	-9	-18	-18	-12	0	0	0	69	-3

Innate Pharma Sa Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	12	-48	3	-20	-63	-52	-58	-7	-49
Operating Cash Flow	-36	-48	-32	34	-51	-58	-19	-32	-6
Investing Cash Flow	60	-29	24	-62	-13	0	1	20	9
Financing Cash Flow	0	0	61	77	-1	26	-1	-1	-6
Change in Cash	23	-76	52	50	-66	-33	-19	-13	-4

Global Institutional Holdings in Innate Pharma Sa

Funds	Holdings
Exchange Traded Concepts, LLC	0.07%
Morgan Stanley - Brokerage Accounts	0.05%
Citadel Advisors Llc	0.03%
Millennium Management LLC	0.02%
UBS Group AG	0.01%

See all

Insights on Innate Pharma Sa

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -24.76M → -24.70M (in $), with an average increase of 0.2% per quarter
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.5% return, outperforming this stock by 148.7%
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.9% return, outperforming this stock by 76.5%
NEGATIVE IMPACT
Price Dip
In the last 1 month, IPHA stock has moved down by -6.9%
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 3 quarters, 21.44M → 276.0K (in $), with an average decrease of 70.1% per quarter

About Innate Pharma Sa

innate pharma s.a. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system. innate pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells. the company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs. innate pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of natural killer cell biology. this innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including astrazeneca, bristol-myers squibb, novo nordisk a/s and sanofi. innate pharma

Organisation	Innate Pharma Sa
Headquarters	117, Avenue de Luminy, Marseille, France, 13009
Industry	Health Technology
CEO	Mr. Jonathan E. Dickinson B.Sc., M.B.A.
E-voting on shares	Click here to vote

Key Management of Innate Pharma Sa

Name	Title
Dr. François Romagné Ph.D.	Founder
Mr. Jean Jacques Fournié Ph.D.	Founder
Mr. Alessandro Moretta M.D., Ph.D.	Founder
Mr. Frederic Lombard M.B.A.	Senior VP & CFO
Mr. Henry Wheeler M.Sc.	Vice President of Investor Relations & Communication
Mr. Yannis Morel Ph.D.	Executive VP & COO
Dr. Sonia Quaratino M.D., Ph.D.	Executive VP & Chief Medical Officer
Dr. Marc Bonneville Ph.D.	Founder
Mr. Jonathan E. Dickinson B.Sc., M.B.A.	CEO & Director
Mr. Eric Vivier D.V.M., M.B.A., Ph.D.	Founder, Senior VP & Chief Scientific Officer

FAQs

What is Innate Pharma Sa share price today?

Innate Pharma Sa share price today is $2 as on September 18, 2025 at 1:28 am IST at the close of the market. Innate Pharma Sa share today touched a day high of $2.16 and a low of $1.96.

What is the 52 week high and 52 week low for Innate Pharma Sa share?

Innate Pharma Sa share touched a 52 week high of $3.51 on December 13, 2024 and a 52 week low of $1.29 on November 18, 2024. Innate Pharma Sa stock price today i.e. September 18, 2025 at 1:28 am IST is closed at $2,which is 43.03% down from its 52 week high and 55.04% up from its 52 week low.

What is Innate Pharma Sa's market capitalisation today?

Innate Pharma Sa market capitalisation is $0.00T as on September 18, 2025 at 1:28 am IST.

How to invest in Innate Pharma Sa Stock (IPHA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Innate Pharma Sa on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Innate Pharma Sa Shares that will get you 0.7500 shares as per Innate Pharma Sa share price of $2 per share as on September 18, 2025 at 1:28 am IST.

What is the minimum amount required to buy Innate Pharma Sa Stock (IPHA) from India?

Indian investors can start investing in Innate Pharma Sa (IPHA) shares with as little as ₹87.816 or $1 (as of September 18, 2025 at 9:42 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Innate Pharma Sa stock (as per the Rupee-Dollar exchange rate as on September 18, 2025 at 9:42 am IST). Based on Innate Pharma Sa share’s latest price of $2 as on September 18, 2025 at 1:28 am IST, you will get 5.0000 shares of Innate Pharma Sa. Learn more about fractional shares .

What are the returns that Innate Pharma Sa has given to Indian investors in the last 5 years?

Innate Pharma Sa stock has given -50.36% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?